An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
This is a Non-interventional, Multicenter study evaluating the efficacy and safety of the combination of pegylated liposomal doxorubicin and trabectedin in routine practice in patients with recurrent partial-platinum sensitive ovarian cancer, which is held in Kazakhstan.
Ovarian Cancer
DRUG: Trabectedin + PLD
Objective Response Rate (ORR), ORR will be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST V 1.1)., Patient will be followed during 37 weeks
Progression-Free Survival (PFS), PFS is defined as the time from the 1st treatment cycle until objective tumor progression or death, Patient will be followed during 37 weeks|Safety according to CTCAE v4.0, To assess patient safety and the tolerance of trabectedin + PLD, Patient will be followed during 37 weeks
This is a Non-interventional, Multicenter study evaluating the efficacy and safety of the combination of pegylated liposomal doxorubicin and trabectedin in routine practice in patients with recurrent partial-platinum sensitive ovarian cancer, which is held in Kazakhstan.